The relationship between cumulative dose of immunosuppressive agents and COVID-19-associated mucormycosis : A multicenter cross-sectional study
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC..
Background and Aims: Immunosuppressive therapy has a key role in developing coronavirus disease-2019 (COVID-19)-associated mucormycosis. In this study, we investigated the effect of the type and cumulative dose of immunosuppressive agents on COVID-19-associated mucormycosis.
Methods: We designed a descriptive cross-sectional study involving three COVID-19 hospitals in Iran. Clinical and demographic data were gathered from the medical records and checked by two independent researchers to minimize errors in data collection.
Results: Seventy-three patients were included in the study. The mean age of cases was 57.41 (SD = 12.64) and 43.8% were female. Among patients, 20.5% were admitted to the intensive care unit (ICU) during COVID-19. Furthermore, 17 patients (23.29%) had a history of diabetes mellitus. Sixty-nine patients (94.52%) had a history of receiving corticosteroids (dexamethasone) during treatment of COVID-19, and of those, five patients (6.85%) received Tocilizumab beside. The mean cumulative dose of corticosteroids prescribed was 185.22 mg (SD = 114.738). The average cumulative dosage of tocilizumab was 720 mg (SD = 178.89). All of the included patients received amphotericin B for mucormycosis treatment, and 42 survived (57.53%). Also, there was a significant relationship between hospitalization in ICU for COVID-19 and the mucormycosis outcome (p = 0.007). However, there weren't any significant associations between cumulative doses of immunosuppressive drugs and mucormycosis outcome (p = 0.52).
Conclusion: The prevalence of COVID-19-associated mucormycosis is increasing and should be considered in the treatment protocols of COVID-19. Controlling risk factors such as diabetes, malignancy and the administration of immunosuppressive agents based on recommended dosage in validated guidelines are ways to prevent mucormycosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Health science reports - 5(2022), 6 vom: 18. Nov., Seite e950 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rastkar, Mohsen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 |
|---|
| Anmerkungen: |
Date Revised 29.11.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/hsr2.950 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349519420 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349519420 | ||
| 003 | DE-627 | ||
| 005 | 20231226042828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hsr2.950 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349519420 | ||
| 035 | |a (NLM)36439042 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rastkar, Mohsen |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The relationship between cumulative dose of immunosuppressive agents and COVID-19-associated mucormycosis |b A multicenter cross-sectional study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.11.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC. | ||
| 520 | |a Background and Aims: Immunosuppressive therapy has a key role in developing coronavirus disease-2019 (COVID-19)-associated mucormycosis. In this study, we investigated the effect of the type and cumulative dose of immunosuppressive agents on COVID-19-associated mucormycosis | ||
| 520 | |a Methods: We designed a descriptive cross-sectional study involving three COVID-19 hospitals in Iran. Clinical and demographic data were gathered from the medical records and checked by two independent researchers to minimize errors in data collection | ||
| 520 | |a Results: Seventy-three patients were included in the study. The mean age of cases was 57.41 (SD = 12.64) and 43.8% were female. Among patients, 20.5% were admitted to the intensive care unit (ICU) during COVID-19. Furthermore, 17 patients (23.29%) had a history of diabetes mellitus. Sixty-nine patients (94.52%) had a history of receiving corticosteroids (dexamethasone) during treatment of COVID-19, and of those, five patients (6.85%) received Tocilizumab beside. The mean cumulative dose of corticosteroids prescribed was 185.22 mg (SD = 114.738). The average cumulative dosage of tocilizumab was 720 mg (SD = 178.89). All of the included patients received amphotericin B for mucormycosis treatment, and 42 survived (57.53%). Also, there was a significant relationship between hospitalization in ICU for COVID-19 and the mucormycosis outcome (p = 0.007). However, there weren't any significant associations between cumulative doses of immunosuppressive drugs and mucormycosis outcome (p = 0.52) | ||
| 520 | |a Conclusion: The prevalence of COVID-19-associated mucormycosis is increasing and should be considered in the treatment protocols of COVID-19. Controlling risk factors such as diabetes, malignancy and the administration of immunosuppressive agents based on recommended dosage in validated guidelines are ways to prevent mucormycosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a immunosuppressive | |
| 650 | 4 | |a mucormycosis | |
| 650 | 4 | |a outcome | |
| 650 | 4 | |a tocilizumab | |
| 700 | 1 | |a SeyedAlinaghi, SeyedAhmad |e verfasserin |4 aut | |
| 700 | 1 | |a Asanjarani, Behzad |e verfasserin |4 aut | |
| 700 | 1 | |a Siri, Goli |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollahi, Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Ghadami, Ladan |e verfasserin |4 aut | |
| 700 | 1 | |a Hasibi, Mehrdad |e verfasserin |4 aut | |
| 700 | 1 | |a Khodashahi, Rozita |e verfasserin |4 aut | |
| 700 | 1 | |a Bagheri, AmirBehzad |e verfasserin |4 aut | |
| 700 | 1 | |a Asadollahi-Amin, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health science reports |d 2018 |g 5(2022), 6 vom: 18. Nov., Seite e950 |w (DE-627)NLM28665525X |x 2398-8835 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2022 |g number:6 |g day:18 |g month:11 |g pages:e950 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hsr2.950 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2022 |e 6 |b 18 |c 11 |h e950 | ||